vamstarReport/Al in Pharma,MedTechBiotech:Unlocking CommercialSuccess→Al in Pharma,MedTech Biotech:Unlocking Commercial SuccessContents01/Executive Summary2Introduction503/Al-Driven Pricing Optimisation04/Enhancing Market Access with Al805/Navigating Loss of Exclusivity(LOE)1006/Integrating Value-Based Procurement(VBP)and ESG1107/Tools and Technologies Powering Al in Life Sciences1208/Conclusion and Next Steps14vamstarAl in Pharma,MedTech Biotech:Unlocking Commercial Success01/Executive SummaryArtificial intelligence (Al)has emerged as atransformative force in the life sciences industry,revolutionising commercial and procurementoperations in pharmaceuticals,medtech,and biotech.By leveraging Al-driven analytics,real-world evidence(RWE),and predictivemodelling,organisations can enhance efficiency,accelerate innovation,anddevelop data-driven strategies to address complex market challenges.Thesechallenges include navigating fragmented regulatory landscapes,optimisingpricing strategies,ensuring cost-efficient operations,and adapting to evolvingvalue-based care models.The lifesciences industry operates in a dynamic regulatory environment,requiring companies to align innovation,affordability,and accessibility withcommercial imperatives such as pricing optimisation,market access,andlifecycle management.Al-powered platforms like Polaris from Vamstar enableorganisations to break down data silos,convert fragmented information intoactionable insights,and develop predictive strategies for sustained growth.However,Al adoption must be tailored to an organisation's unique challenges,making expert engagement and customised solutions essential for maximisingAl's potential and securing competitive advantage.vamstarAl in Pharma,MedTech Biotech:Unlocking Commercial Success01/Executive Summary /continuedKey TakeawaysIMPROVING OPERATING MARGINS:The life sciences industry faces growing pressure to enhance operationalefficiency.With SG&A costs surpassing 40%,agentic automation-encompassing solutions such as sales enablement and CRM automation-unlocks substantial value for organisations.AI AS A STRATEGIC ENABLER:Advanced analytics,Real-World Evidence (RWE),and predictive modelling arereshaping how life sciences organisations address pricing,market access,andsustainability targets.DRIVING REVENUE GROWTH:Al-driven pricing optimisation helps companies reclaim up to 22%of lostvalue caused by outdated or static methodologies.vamstarAl in Pharma,MedTech Biotech:Unlocking Commercial Success01/Executive Summary /continuedSTREAMLINING MARKET ACCESS:Al-powered tools,such as Polaris,simplify navigation of fragmented regulatorylandscapes,ensuring compliance and fostering patient-centric strategies.ESGSUSTAINABILITY AND ESG ALIGNMENT:Al-driven insights enhance transparency in value-based procurement (VBP)and environmental,social,and governance(ESG)decision-making.TAILORED AI SOLUTIONS:Engaging with Al specialists ensures bespoke strategies that align with anorganisation's unique needs and commercial objectives.Contact us→Discover how Al can propel your commercial outcomes,contact us today for a tailored consultation.vamstarAl in Pharma,MedTech Biotech:Unlocking Commercial Success02/IntroductionThe life sciences industry stands at the intersection of evolving global regulations,patient-centric care models,and cost-efficiency pressures.Regulations oftenvary significantly by region,requiring adaptive and agile commercial strategies.Organisations must balance operational efficiencies,pricing optimisation,marketaccess,lifecycle management,and growing demands for transparency in anThese challenges are both interconnected and dynamic.For example:>Pricing Optimisation involves integrating real-world evidence to set competitiveyet justifiable prices.->Market Access strategies demand alignment with payer requirements,regulatoryhurdles,and patient needs across diverse markets.>Lifecycle Management ensures the ongoing viability of products throughapproaches like line extensions,generic launches,and geographic diversification.Al technologies like Vamstar's Polaris Agentic platform offer data orchestration,advanced analytics,and predictive modelling to tackle these complexities.Polarisconverts fragmented data into actionable insights,guiding life sciences companiestowards data-driven decisions.Engaging with expert partners who can tailor Alsolutions is critical for achieving sustainable growth and competitive advantage.Selecting the right partner is even more critical,Vamstar not only brings cuttingedge Al technology to support your commercial goals but also supports yourorganisation with combined industry experience exceeding 75 years.vamstarAl in Pharma,MedTech Biotech:Unlocking Commercial Success03/Al-Driven PricingOptimisationPricing is a vital lever for revenue growth,yet many organisations still rely on manualor outdated tools.Our extensive research indicates up to 22%of potential value isleft untapped in every pricing decision-from launch to late-stage lifecycle.Dynamic Pricing and Predictive AnalyticsMachine learning models assess market trends,buyer behaviours,andprocurement patterns in real-time.Vamstar's Pricing Co-Pilot,powered by Polaris,improves tender win rates andrevenue forecasting,even for early-stage assets.Value-Based Pricing (VBP)>Al aligns pricing with clinical and economic outcomes,vital in a value-basedhealthcare model.By scanning vast clinical and real-world datasets,Vamstar's algorithmspredict and justify pricing based on health technology assessments and payerexpectations.vamstarAl in Pharma,MedTech Biotech:Unlocking Commercial Success03/Al-Driven Pricing Optimisation continuedRegional and Global Harmonisation>Al-powered insights inform tiered pricing strategies that cater to distincteconomic conditions.Incorporating data from multiple markets ensures coherence and optimisesprice points for each segment.Contact us→Capture more value in your pricing decisions.Speak with our Al specialists to explore tailored strategiesfor your portfolio..00088848vamstarAl in Pharma,MedTech Biotech:Unlocking Commercial Success04/Enhancing MarketAccess with AlMarket access in life sciences is a multi-dimensional challenge,encompassingprocurement strategies,reimbursement negotiations,regulatory compliance,andpatient outreach.Al-driven tools play a crucial role in streamlining these processesby automating data analysis,identifying policy changes in real-time,and providingpredictive insights to anticipate market trends.By leveraging Al-powered platformslike Polaris,organisations can enhance their ability to navigate fragmentedregulatory environments,align with payer requirements,and ensure timely patientaccess to life-saving treatments.vamstarAl in Pharma,MedTech Biotech:Unlocking Commercial Success04 Enhancing Market Access with Al continuedEvidence Mapping>Vamstar's Market Access Component,powered by Polaris,autonomouslycollates policy evidence and clinical data.>Prioritise critical evidence and pinpoint policy changes that directly influence yourorganisation's procurement strategy.Policy Tracking>Continuous monitoring of regulatory landscapes (including sustainability andESG regulations)keeps your commercial efforts aligned and compliant.>Real-time alerts enable rapid strategy adjustments,minimising the risk ofnon-compliance.Patient-Centric Strategies>Al-driven market access ensures solutions are designed around patientoutcomes and payer requirements.>This alignment fosters stronger stakeholder collaboration and smootherreimbursement pathways.vamstarAl in Pharma,MedTech Biotech:Unlocking Commercial Success05/Navigating Loss ofExclusivity (LOE)Facing generic and biosimilar competition is inevitable in pharmaceuticals.Al helpsmanage the patent cliff by guiding proactive,data-driven lifecycle management.Byleveraging predictive analytics and real-world evidence,organisations can anticipatemarket shifts,optimise pricing strategies,and enhance portfolio planning.Al-drivenlifecycle strategies also support early identification of differentiation opportunities,such as combination therapies or innovative formulations,helping pharmaceuticalcompanies maintain market presence and maximise revenue potential beyondpatent expiration.Predictive Market AnalyticsAl models anticipate demand shifts and competitor moves,enabling timelyadjustments in lifecycle strategies.>Organisations can identify potential gaps in their portfolio and plan productextensions or market expansions accordingly.Lifecycle Management>Al identifies opportunities for innovation,such as line extensions,co-formulations,and in-house generics.>One generics manufacturer using Vamstar's Al achieved an 80%boost in tenderwin rates,recouping e2.8 million in revenue on a single molecule.10vamstarAl in Pharma,MedTech Biotech:Unlocking Commercial Success06/Integrating Value-BasedProcurement (VBP)and ESGProcurement is being reshaped by frameworks that emphasise both patientoutcomes and environmental impact.Al aligns these objectives to transformprocurement processes.Unified Frameworks>Al consolidates disparate data sources,linking procurement decisions tosustainability and value-based metrics.>This creates a cohesive view of cost-effectiveness,patient benefit,and ESGoutcomes.Evidence and Impact TrackingAl systems map clinical data alongside ESG factors,enabling transparent andresponsible procurement.>Tools like Vamstar's ValueGPT measure outcomes against sustainability metrics,ensuring accountability.vamstarAl in Pharma,MedTech Biotech:Unlocking Commercial Success07Tools and TechnologiesPowering Al in LifeSciencesThe Polaris platform underpins Vamstar's suite of Al-driven tools,designed to solvethe most pressing challenges in pharmaceuticals,medtech,and biotech.Market Access ComponentAutonomously gathers and analyses policy and clinical evidence.>Delivers strategic insights for proactive procurement and regulatory alignment.Price Optimisation>Industry-specific machine learning models for dynamic and value-based pricing.>Ensures maximum tender success rates with minimal revenue leakage.Contract Management and CRM Automation>Streamlines contract discovery and analysis,reducing manual data entry.>Enables rapid opportunity filtering and automatic updates in CRM for fasterresponses in a competitive market.12vamstarAl in Pharma,MedTech Biotech:Unlocking Commercial Success07 Tools and Technologies Powering Al in Life Sciences/continuedPricing Co-Pilot>Integrates predictive analytics and automated pricing decisions>Helps organisations enhance tender bidding processes and optimiserevenue growth.Contact us→30%of sales and commercial teams'time is spent ondata entry.Take a step forward today.Request a demo ofVamstar's agentic solutions to learn more.Why Polaris?Polaris is our advanced agentic Al-powered data integration,analytics,andpredictive modelling platform designed to help organisations in life sciencesmanage,analyse,and derive insights from their data at scale.By breaking downdata silos and transforming raw data into actionable knowledge,Polaris enablesenterprises to optimise workflows while empowering decision-makers to makedata-driven choices.13vamstarAl in Pharma,MedTech Biotech:Unlocking Commercial Success08/Conclusion andNext StepsAl is revolutionising commercial operations across the life sciences industry.Many leading pharmaceutical and medtech companies are integrating Al to boostrevenue,sharpen margins,and gain a competitive edge.The question today is nolonger whether to implement Al but rather who to trust for its effective deployment.Unlike generalist Al providers,Vamstar is exclusively focused on the life sciencesindustry,offering deep domain expertise and insights well beyond the scopeof broader Al solutions.To fully explore how Al can transform your commercialstrategies,speak to our specialists.We'll work with you to develop and implementan approach tailored to your portfolio,market challenges,and long-termbusiness goals.vamstar